Clinical Outcomes of a Customized Mitral Valve Plasty for Functional Mitral Regurgitation with a Low Ejection Fraction and Implications for Preoperative Right Ventricular Function

• Published in: Annals of Thoracic and Cardiovascular Surgery Vol. 27; no. 1; pp. 32 - 40
• Main Authors: Furukawa, Koji, Yano, Mitsuhiro, Ishii, Hirohito, Sakaguchi, Shuhei, Mori, Kousuke, Nishimura, Masanori, Nakamura, Kunihide
• Format: Journal Article
• Language: English
• Published: Japan The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery 01.01.2021
• Subjects: functional mitral regurgitation; mitral valve plasty; Original; right ventricular function; RVFAC; subvalvular procedure; subvalvular procedure; functional mitral regurgitation; right ventricular function; RVFAC; mitral valve plasty
• ISSN: 1341-1098; 2186-1005
• DOI: 10.5761/atcs.oa.20-00035

Purpose: To evaluate clinical outcomes of customized mitral valve plasty (MVP) for the treatment of functional mitral regurgitation (FMR) with a low ejection fraction (EF) and to determine which preoperative factors affected the clinical outcome.Methods and Results: MVP was adjusted according to the degree of left ventricle (LV) remodeling. We performed mitral annuloplasty (MAP) alone in 14 patients and added subvalvular procedures (SVPs) in 22 patients at a high risk of recurrent MR. During follow-up, reverse LV remodeling was obtained and the 3-year and 5-year non-recurrence rates of MR grade ≥2 were 94% and 89%, respectively. Two patients died during their hospital stay, and four more patients died of cardiac causes during follow-up. The 3-year and 5-year rates of freedom from cardiac-related mortality were 86% and 81%, respectively; no significant difference was observed between the two treatment groups. Right ventricular fractional area change (RVFAC) was a significant predictor of cardiac mortality. Patients with an RVFAC of <26% had significantly poorer cardiac-related mortality (71% at 3 years) than those with an RVFAC of ≥26% (95% at 3 years).Conclusion: Customized MVP provided durable mitral competence and reverse LV remodeling. Preoperative RV function was associated with cardiac-related mortality.